As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.

How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.

Memo outlines how US agency ensured sufficient delivery of updated COVID-19 vaccine doses even as it navigated unresolved inspection findings of the Catalent plant where the additional doses had been manufactured.

Merging with the shell of troubled cancer biotech Sesen, Carisma believes its chimeric antigen-receptor-macrophage (CAR-M) platform can bring the immunotherapy application to solid tumors.